Increases facility by $150 million and extends it to 2026 RARITAN, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) ("Ortho"), one of the world's largest pure-play in vitro diagnostics companies, today announced that certain of its subsidiaries

RARITAN, N.J. , Feb. 4, 2021 /PRNewswire/ --  Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) ("Ortho"), the world's largest pure-play in vitro diagnostics company dedicated to improving and saving lives through innovative laboratory testing and blood-typing solutions, today announced the

RARITAN, N.J. , Jan. 27, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics Holdings plc ("Ortho"), the world's largest pure-play in vitro diagnostics company dedicated to improving and saving lives through innovative laboratory testing and blood-typing solutions, today announced the pricing of its

​​​​​ Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, today announced that it was recognized with  MedTech’s 2020 Outstanding Contribution to the Bio/Med Industry Award  for its  diagnostic solutions to the COVID-19 pandemic . Ortho was the first company to receive Emergency

Ortho’s VITROS® SARS-CoV-2 Antigen Test is the first high-volume COVID-19 antigen test to receive Food and Drug Administration (FDA) Emergency Use Authorization (EUA). With utility for mass-scale testing and same-day results for labs, Ortho’s latest COVID-19 solution can run up to 130 tests per

Ortho Clinical Diagnostics, a global leader of in vitro diagnostics dedicated to improving and saving lives through innovative laboratory solutions, today announced the CE Mark availability of the semi-automated ORTHO Optix™ Reader, which allows lower-volume transfusion labs to elevate their

Ortho Clinical Diagnostics (“Ortho”), today announced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the “SEC”) relating to its proposed initial public offering. The number of shares to be offered and the price range for

Ortho Clinical Diagnostics, a global leader of in vitro diagnostics and the global market leader for transfusion medicine diagnostics, is pleased to announce a full slate of events at the 2020 AABB Annual Meeting, to be held virtually Oct. 3-5. Ortho’s programming will focus on the company’s

Noted Diagnostic Industry Veteran David B. Perez Joins as an Independent Director. Chris Smith Appointed Chairman of the Board, in addition to current CEO role. Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, today announced that David B.

Ortho Clinical Diagnostics, a global leader of in vitro diagnostics with a worldwide reputation for top-rated customer service and support, today announced that its Ortho Care™ holistic service and support program was ranked No. 1 in the diagnostics industry for a fifth straight year.